Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Cash & Equivalents data on record, last reported at $4.1 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 3.11% year-over-year to $4.1 million; the TTM value through Sep 2025 reached $4.1 million, down 3.11%, while the annual FY2024 figure was $3.8 million, 35.85% down from the prior year.
  • Cash & Equivalents reached $4.1 million in Q3 2025 per RANI's latest filing, down from $10.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $129.7 million in Q3 2021 and bottomed at $3.8 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $36.5 million, with a median of $10.2 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 775.62% in 2021, then tumbled 92.23% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $117.5 million in 2021, then crashed by 77.01% to $27.0 million in 2022, then tumbled by 78.29% to $5.9 million in 2023, then crashed by 35.85% to $3.8 million in 2024, then grew by 10.15% to $4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.1 million in Q3 2025, $10.2 million in Q2 2025, and $10.1 million in Q1 2025.